Valsartan Synthesis via Reductive Amination and One-Pot N-Acylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing Valsartan face challenges such as the use of hazardous reagents like sodium azide, environmental concerns, high molecular weight intermediates due to bulky protective groups, low atomic efficiency, and racemization issues, making them unsuitable for industrial-scale production with high yields and safety.
Innovation Solution
A process involving reductive amination of a benzaldehyde with L-Valine salts in a polar solvent, followed by acidification and N-acylation with valeryl chloride, without the need for protective groups, to obtain the intermediate with high yields and optical purity, using a one-pot reaction to minimize steps and prevent racemization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bulky protective groups (trityl for tetrazole, benzyl for carboxylic acid) are used in Valsartan synthesis, then the tetrazole ring and carboxylic acid are protected, but the molecular weight of intermediates increases considerably and atomic efficiency decreases
Solution Approach 1:
The invention extracts and eliminates the bulky protective groups (trityl and benzyl) from the synthesis pathway. Instead of protecting the tetrazole ring and carboxylic acid group, the process uses the free forms directly in the coupling reaction, thereby avoiding the addition of extra atoms that会降低 atomic efficiency while still achieving the desired protection of functional groups through reaction conditions control
Solution Approach 2:
The invention changes the reaction parameters, specifically using a one-pot sequential reaction approach where the order and conditions of reactions are optimized to prevent unwanted side reactions without protective groups. The pH control and sequential addition of reagents allow the process to proceed with high selectivity without requiring additional protecting groups
2Reliability
If sodium azide or tributyl tin azide is used in the synthesis steps, then the tetrazole ring is formed, but safety risks of explosions or environmental problems occur
Solution Approach 1:
The invention converts the harmful azide reagents into a safer alternative by using a different chemical pathway. Instead of using sodium azide or tributyl tin azide which pose safety and environmental risks, the process employs a sequential reaction mechanism where the tetrazole ring is formed through a different transformation that avoids hazardous materials while maintaining the desired chemical outcome
Solution Approach 2:
The invention replaces expensive and hazardous reagents with more benign alternatives. The new methodology uses readily available, non-hazardous reagents that can be easily handled and disposed of, eliminating the need for special safety precautions associated with azide compounds while achieving the same synthetic objective
3Reliability
If multiple synthesis steps with protective groups are used, then functional groups are protected, but the number of synthesis steps increases and production efficiency decreases
Solution Approach 1:
The invention merges multiple separate synthesis steps into a single one-pot sequential reaction. By combining the coupling reaction and subsequent transformations in one reaction vessel without isolating intermediates, the process reduces the number of operational steps while maintaining the protection of functional groups through controlled reaction conditions and sequential reagent addition
Solution Approach 2:
The invention performs preliminary preparation of reagents and optimization of reaction conditions before the main transformation. This includes pre-mixing certain components, adjusting pH levels, and establishing the correct sequence of additions to ensure that the reaction proceeds smoothly without requiring protective groups, thereby reducing the overall number of steps needed
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yields and optical purity of the intermediate, reducing waste and safety concerns, enabling industrial-scale production of Valsartan with improved atomic efficiency and simplified purification.
Implementation Method 1
A process involving reductive amination of a benzaldehyde with L-Valine salts in a polar solvent
Implementation Method 2
followed by acidification and N-acylation with valeryl chloride
Data Source
AI summary
The invention provides a method for obtaining the intermediate (II), useful for manufacturing Valsartan and a drug directed to a treatment of arterial hypertension or heart failure. The process comprises a) Imination of the aldehyde group of a compound (VII) by L-Valine (IV) salts with organic or inorganic bases and a polar solvent or water, where X means halogen or an-OSO2R group, where R is CF3, tolyl, methyl or F; to give an imine-type compound (VIII), where B+ is the protonated form of an organic base or an alkaline cation; b) Reduction of the imine group of the compound (VIII) followed by acidification, to give the compound (VI); and c) N-Acylation of the compound (VI) with valeryl chloride to give the compound (II). Steps a) and b) can be performed in a "one pot" reaction.